Navigating advanced #HCC: treatment strategies beyond immunotherapy (IO). ➡️ Exploring treatment strategies for pts ineligible for IO or those w/ progression on #IO. 🎓 Micro learning from Dr @docamitgs + Assoc. Prof. @LorenzaRimassa. Go to the video/resources/assessment:

HCC micro learning ⬇️. The expanding role of immunotherapy in HCC - Combining locoregional & systemic treatments in intermediate HCC. A concise video, slides, flashcard & accredited assessment 👉 Endorsed by @dice_europe @GlobalLiver @EuropeLiver

📢 Treatment strategies for pts with advanced HCC who are ineligible for #immunotherapy or with progression on #IO. >> See the flashcard! Click the image in this post to enlarge 🔍. 🤝 Endorsed by: @dice_europe @GlobalLiver @EuropeLiver @BlueFaeryLiver @AASLDtweets. Go to the

Infographic: Insights from the Phase 3 LEAP-012 study! . ➡️Evaluating lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate HCC . . This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had

Get expert insights from the Phase 3 LEAP-012 study evaluating lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate HCC. 👉 Locoregional therapies combined with IO-based therapies should be more frequently considered in clinical practice,

🎓Test your knowledge of #IO for intermediate #HCC!. Topics include:. 🔸 The expanding role of IO and IO combinations for pts w/ unresectable HCC.🔸 The latest data + expert views on IO in combination w/ locoregional therapies.🔸 The role of the multidisciplinary team

HCC micro learning ⬇️. The expanding role of immunotherapy in HCC - Combining locoregional & systemic treatments in intermediate HCC. A concise video, slides, flashcard & accredited assessment.👉 Endorsed by @dice_europe @GlobalLiver @EuropeLiver

🎉COR2ED has over 12k subscribers on YouTube! 🎉. Do you follow us?.▶️ Join over 12k HCPs on our YouTube channel and stay up to date with #MedEd videos as they’re released 🎓. #MedicalEducation #Oncology #HCC

RT @dice_europe: 📣#COR2ED has recently released a new, highly relevant micro-learning programme for healthcare professionals working in the….

👉 After progression on 1st line IO, multiple treatment strategies are available in advanced HCC. 👉 If a clinical trial is not available, switching to a TKI or considering alternative IO-based approaches may be viable options based on:. ✅ patient eligibility.✅ disease

👉 LEAP-012 further supports the approach of combining locoregional therapies with IO-based therapies. Prof. Arndt Vogel shares his clinical takeaways from the LEAP-012 publication:. This programme has been sponsored by Eisai Europe Limited ("Eisai").

📢 Treatment strategies for pts w/ advanced HCC who are ineligible for #immunotherapy or with progression on #IO. 📺 Accredited micro learning: 🤝 Endorsed by: @dice_europe @GlobalLiver @EuropeLiver @BlueFaeryLiver @AASLDtweets. Supported by an

Experts discuss the latest clinical trial data (EMERALD-1, LEAP-012) and their views on combining IO with loco-regional therapies for #HCC. What are the clinical implications of these data in practice?. A #MedEd video podcast 📹. Listen to the full conversation on the go on

There is a cohort of patients with advanced HCC who are not eligible for immunotherapy as 1st line treatment option. Follow an interactive patient case with Prof. Sammy Saab to explore treatment decisions, manage AEs, and plan next steps after progression. 👀 Watch now:

HCC continues to pose a major global burden. This comprehensive review of the BSG’s updated HCC guidelines outlines key updates and underscores the persistently high—and unacceptable—mortality rates associated with the disease. #MedEd.

Thank you @LorenzaRimassa for all your work on this and for sharing!.

📢 New #HCC micro learning!. What treatment strategies are available for patients with advanced HCC who are ineligible for #immunotherapy or with progression on #IO?. 📺 Video/slides/assessment from Dr Amit Singal (@docamitgs) & Assoc. Prof. @LorenzaRimassa. Go to the micro